Anebulo Pharmaceuticals (ANEB) reported a fiscal Q4 loss late Monday of $0.05 per diluted share, unchanged from a year earlier.
An analyst polled by FactSet expected $0.05 loss.
The company did not report any revenue for the quarter ended June 30.
As of June 30, the company said it had $11.6 million in cash and cash equivalents. It also has access to another $3 million in cash via a loan agreement.